CN101053619A - 一种治疗肺纤维化的药物 - Google Patents
一种治疗肺纤维化的药物 Download PDFInfo
- Publication number
- CN101053619A CN101053619A CNA2006100207163A CN200610020716A CN101053619A CN 101053619 A CN101053619 A CN 101053619A CN A2006100207163 A CNA2006100207163 A CN A2006100207163A CN 200610020716 A CN200610020716 A CN 200610020716A CN 101053619 A CN101053619 A CN 101053619A
- Authority
- CN
- China
- Prior art keywords
- medicine
- radix
- parts
- pulmonary fibrosis
- sanguis draxonis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 96
- 208000005069 pulmonary fibrosis Diseases 0.000 title claims abstract description 33
- 229940079593 drug Drugs 0.000 title claims description 37
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 34
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 34
- 235000008434 ginseng Nutrition 0.000 claims abstract description 34
- 241000208340 Araliaceae Species 0.000 claims description 33
- 235000011201 Ginkgo Nutrition 0.000 claims description 26
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 26
- 210000000582 semen Anatomy 0.000 claims description 26
- 241000283956 Manis Species 0.000 claims description 25
- 239000009286 sanguis draxonis Substances 0.000 claims description 25
- 241000592346 Ginkgophyta Species 0.000 claims description 16
- 241000218628 Ginkgo Species 0.000 claims description 10
- 239000006187 pill Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000006196 drop Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000007902 hard capsule Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000007901 soft capsule Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 12
- 244000194101 Ginkgo biloba Species 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 241000283966 Pholidota <mammal> Species 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 240000004824 Trimezia steyermarkii Species 0.000 abstract 1
- 239000009136 dragon's blood Substances 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 235000005412 red sage Nutrition 0.000 abstract 1
- 239000000835 fiber Substances 0.000 description 21
- 210000004072 lung Anatomy 0.000 description 21
- 239000000126 substance Substances 0.000 description 19
- 239000000463 material Substances 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 201000010099 disease Diseases 0.000 description 13
- 206010001889 Alveolitis Diseases 0.000 description 12
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 12
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 12
- 241000700159 Rattus Species 0.000 description 9
- 125000002324 prednisone group Chemical group 0.000 description 7
- 206010016654 Fibrosis Diseases 0.000 description 6
- 230000004761 fibrosis Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 108010006654 Bleomycin Proteins 0.000 description 3
- 206010020880 Hypertrophy Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 108700004675 bleomycetin Proteins 0.000 description 3
- 229960001561 bleomycin Drugs 0.000 description 3
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 3
- QYOAUOAXCQAEMW-UTXKDXHTSA-N bleomycin A5 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCNCCCCN)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QYOAUOAXCQAEMW-UTXKDXHTSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 208000037920 primary disease Diseases 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 210000003437 trachea Anatomy 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- 239000009636 Huang Qi Substances 0.000 description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 208000029523 Interstitial Lung disease Diseases 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 206010062049 Lymphocytic infiltration Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 241000053227 Themus Species 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000007596 consolidation process Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 241000756943 Codonopsis Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241001489978 Eupolyphaga Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 241000131808 Scolopendra Species 0.000 description 1
- 241000522620 Scorpio Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- IYPRWQPJYRBHIS-UHFFFAOYSA-N acetic acid;uranium Chemical compound [U].CC(O)=O IYPRWQPJYRBHIS-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000012137 double-staining Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229940085805 fiberall Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- -1 hydroxypropyl Chemical group 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 229940102542 prednisone 5 mg Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 208000037922 refractory disease Diseases 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 239000009490 scorpio Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
组别 | 鼠数 | 肺系数 |
空白组模型组化纤方高剂量组化纤方中剂量组化纤方低剂量组***组 | 888888 | 6.35±0.259.24±0.32△6.95±0.23▲7.11±0.17▲*7.85±0.34▲7.95±0.28▲ |
组别 | 鼠数 | 肺泡炎程度 | 肺纤维化程度 | ||||||
0级 | I级 | II级 | III级 | 0级 | I级 | II级 | III级 | ||
空白组模型组化纤方高剂量组化纤方中剂量组化纤方低剂量组***组 | 888888 | 805421 | 042343 | 031113 | 010011 | 801100 | 016314 | 031342 | 040132 |
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006100207163A CN101053619B (zh) | 2006-04-14 | 2006-04-14 | 一种治疗肺纤维化的药物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006100207163A CN101053619B (zh) | 2006-04-14 | 2006-04-14 | 一种治疗肺纤维化的药物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101053619A true CN101053619A (zh) | 2007-10-17 |
CN101053619B CN101053619B (zh) | 2011-02-16 |
Family
ID=38793785
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006100207163A Expired - Fee Related CN101053619B (zh) | 2006-04-14 | 2006-04-14 | 一种治疗肺纤维化的药物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101053619B (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101780065A (zh) * | 2010-03-17 | 2010-07-21 | 天津金耀集团有限公司 | 依地酸钙钠在制备抑制人或哺乳动物***生长因子、单胺氧化酶药物中的应用 |
CN102225154A (zh) * | 2011-06-16 | 2011-10-26 | 成都中医药大学 | 一种治疗肺纤维化的药物组合物 |
CN102225155A (zh) * | 2011-06-16 | 2011-10-26 | 成都中医药大学 | 一种治疗肺纤维化的药物组合物 |
CN105395816A (zh) * | 2015-11-10 | 2016-03-16 | 浙江锦天生物科技有限公司 | 一种治疗肺纤维化的中药组合物及其制备方法 |
CN105497710A (zh) * | 2014-10-28 | 2016-04-20 | 程学来 | 一种治疗肺囊性纤维化的中药 |
CN115282221A (zh) * | 2022-07-26 | 2022-11-04 | 上海中医药大学附属曙光医院 | 一种治疗特发性肺纤维化的中药组合物及其应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1593587A (zh) * | 2004-06-28 | 2005-03-16 | 黄资源 | 一种治疗肺系疾病的养肺理肺丸及其制备方法 |
-
2006
- 2006-04-14 CN CN2006100207163A patent/CN101053619B/zh not_active Expired - Fee Related
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101780065A (zh) * | 2010-03-17 | 2010-07-21 | 天津金耀集团有限公司 | 依地酸钙钠在制备抑制人或哺乳动物***生长因子、单胺氧化酶药物中的应用 |
CN102225154A (zh) * | 2011-06-16 | 2011-10-26 | 成都中医药大学 | 一种治疗肺纤维化的药物组合物 |
CN102225155A (zh) * | 2011-06-16 | 2011-10-26 | 成都中医药大学 | 一种治疗肺纤维化的药物组合物 |
CN102225154B (zh) * | 2011-06-16 | 2012-07-25 | 成都中医药大学 | 一种治疗肺纤维化的药物组合物 |
CN102225155B (zh) * | 2011-06-16 | 2012-08-22 | 成都中医药大学 | 一种治疗肺纤维化的药物组合物 |
CN105497710A (zh) * | 2014-10-28 | 2016-04-20 | 程学来 | 一种治疗肺囊性纤维化的中药 |
CN105395816A (zh) * | 2015-11-10 | 2016-03-16 | 浙江锦天生物科技有限公司 | 一种治疗肺纤维化的中药组合物及其制备方法 |
CN115282221A (zh) * | 2022-07-26 | 2022-11-04 | 上海中医药大学附属曙光医院 | 一种治疗特发性肺纤维化的中药组合物及其应用 |
CN115282221B (zh) * | 2022-07-26 | 2023-09-15 | 上海中医药大学附属曙光医院 | 一种治疗特发性肺纤维化的中药组合物及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN101053619B (zh) | 2011-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1742939A (zh) | 一种治疗肺间质纤维化的药物及其制备方法 | |
CN101053619A (zh) | 一种治疗肺纤维化的药物 | |
CN1267144C (zh) | 复方消渴清糖降脂制剂及其制备方法 | |
CN101028325A (zh) | 一种含有塞隆骨的药物组合物及其制备方法和质量控制方法 | |
CN101041037A (zh) | 一种治疗糖尿病肾病的药物组合及其制备方法 | |
CN1304735A (zh) | 一种治疗慢性结肠炎的药物 | |
CN1857605A (zh) | 治疗慢性酒精中毒性肝病的药物及其制备方法 | |
CN1973850A (zh) | 一种治疗过敏性鼻炎的药物组合物及其制备方法 | |
CN1148217C (zh) | 治疗慢性支气管炎的中成药 | |
CN1051713C (zh) | 双苓止泻口服液及其生产工艺 | |
CN1195540C (zh) | 一种治疗慢性***炎的药物及其制备方法 | |
CN1259961C (zh) | 治疗肾病的药物及其制备方法 | |
CN1883641A (zh) | 一种治疗脾肾阳虚和抗衰健身的药物及其制备方法 | |
CN1313126C (zh) | 一种治疗高血脂症的散剂及其制备方法 | |
CN1253188C (zh) | 一种治疗高血压的药物及其制备方法 | |
CN1220515C (zh) | 一种治疗咽喉疾病的药物 | |
CN1259953C (zh) | 一种抗衰老保健药物 | |
CN1225277C (zh) | 一种治疗癫痫病的中药组合物及其制备方法 | |
CN1579514A (zh) | 一种治疗慢性肾功能衰竭的药物及其制备方法和用途 | |
CN1274353C (zh) | 一种防治儿童疳积的药物及其制备方法 | |
CN1126554C (zh) | 一种用于治疗乳腺小叶增生症的注射液 | |
CN100344301C (zh) | 一种治疗白癜风病口服药物及其制造方法 | |
CN1872229A (zh) | 一种颈复康片及其制备方法 | |
CN1883614A (zh) | 养发乌发制剂的配方及制备方法 | |
CN1544077A (zh) | 一种治疗咽喉慢喉喑症状的中药及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: LI WENJUN Owner name: CHENGDU UNIVERSITY OF CHINESE MEDICINE Free format text: FORMER OWNER: LI RONG Effective date: 20101026 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 610071 BUILDING 3, NO.7, YINXING ROAD, CHENGDU CITY, SICHUAN PROVINCE TO: 611137 NO.1166, LIUTAI AVENUE, WENJIANG DISTRICT, CHENGDU CITY, SICHUAN PROVINCE |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20101026 Address after: 611137 Sichuan, Chengdu Province, Liu Road, Wenjiang District No. 1166 Applicant after: Chengdu University of Traditional Chinese Medicine Address before: 3, 7, 610071 ginkgo Road, Sichuan, Chengdu Applicant before: Li Rong Co-applicant before: Li Wenjun |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110216 Termination date: 20140414 |